Jurgi Camblong

TLDR

Jurgi Camblong is founder and CEO of SOPHiA GENETICS, a Switzerland-based AI-powered genomic data analysis company with Belgian investor roots through Alychlo.

Overview

Jurgi co-founded SOPHiA GENETICS in 2011 alongside Dr. Pierre Hutter and Prof. Lars Steinmetz. He is a molecular biologist with publications in Cell, Science, and Nature, and holds a PhD in life sciences from the University of Geneva as well as an EMBA from EPFL/HEC Lausanne. The company was named among the 50 Smartest Companies by MIT Technology Review.

SOPHiA GENETICS has been a pioneer in data-driven medicine since its founding, enabling cloud-native genomics in hospitals worldwide. The company went public on NASDAQ in 2021 and has expanded its platform to include decentralised liquid biopsy and multimodal AI for oncology, cardiology, and rare disease. Alychlo, Marc Coucke's investment vehicle, is a shareholder.

Career Highlights

• Founded SOPHiA GENETICS in 2011, led it through Series D and a NASDAQ IPO (2021)
• Named EY Emergent Entrepreneur of the Year in 2017
• Member of the Advisory Council on Digital Transformation to the Swiss government

Connections

SOPHiA GENETICS has a Belgian investor connection through Alychlo. The company is a reference case for European deep-tech in genomics and AI-driven diagnostics.